Polpharma's acquisition of part of Bioton has been approved
by UOKiK.
Polpharma SA is Polish manufacturer of drugs and active
pharmaceutical ingredients. Bioton SA produces mainly
pharmaceuticals used for injections, including recombined human
insulin and other biotechnological drugs.
Polpharma is acquiring the part of its business relating to
Biodacyna, a drug used to treat eye infections.
Polish competition law requires UOKiK to be notified of an
intended merger where the combined turnover of the merging parties
in the preceding financial year exceeds €1 billion
worldwide or €50 million in Poland.
This article was written for Law-Now, CMS Cameron
McKenna's free online information service. To register for
Law-Now, please go to www.law-now.com/law-now/mondaq